Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...

Capital B publishes its results for the first half of 2025

Group EBITDA of (€634k), including costs related to the Bitcoin Treasury Company strategy of €1.2m* Adjusted EBITDA of the Group's historical operating entities IORGA & TRIMANE ...

Why IT leaders should pay attention to Canva’s ‘imagination era’ strategy

For technology teams, Canva’s approach offers important lessons, including a commitment to openness. “There are so many ...

Why your SEO and PPC teams need shared standards to unlock mutual gains

Mutualism between SEO and PPC lowers costs, speeds insights, and builds sustainable visibility across organic and paid search ...